Optimization of aminoglycoside therapy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2528-2531

  Drusano, G L ^a   Louie, Arnold ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BAYES THEOREM; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY; MICROBIAL SENSITIVITY TESTS;

EID: 79956330776     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01314-10     Document Type: Article

References (12)

1. Chuck, S. K., S. R. Raber, K. A. Rodvold, and D. Areff. 2000. National survey of extended-interval aminoglycoside dosing. Clin. Infect. Dis. 30:440-441.
2. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
3. Drusano, G. L., et al. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760.
4. Endimiani, A., et al. 2009. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:4504-4507.
5. Inciardi, J. F., and K. K. Batra. 1993. Nonparametric approach to population pharmacokinetics in oncology patients receiving aminoglycoside therapy. Antimicrob. Agents Chemother. 37:1025-1027.
6. Kashuba, A. D., A. N. Nafziger, G. L. Drusano, and J. S. Bertino, Jr. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 43:623-629.
7. Lin, G., L. M. Ednie, and P. C. Appelbaum. 2010. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob. Agents Chemother. 54:2258-2261.
8. Lodise, T. P., et al. 2011. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrobial Agents Chemother. 55:1606-1610.
9. Mingeot-Leclercq, M. P., and M. P. Tulkens. 1999. Aminoglycosides: nephrotoxicity. Antimicrob. Agents Chemother. 43:1003-1012.
10. Nicolau, D. P., et al. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
11. Rybak, M. J., et al. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
12. Uchino, S., et al. 2005. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818.